Fennec is a newly profitable, debt-free specialty pharma with protected PEDMARK sales, high-margin operating leverage, and asymmetric upside if pediatric adoption expands into the much larger AYA and adult oncology markets.
Overview
Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss in cancer patients. Its flagship sodium thiosulfate product is sold as PEDMARK® in the U.S. and PEDMARQSI® internationally. Revenue comes from direct U.S. product sales and ex-U.S. licensing economics through Norgine, including upfront payments, milestones, and royalties. The company benefits from high gross margins, regulatory protection, FDA non-substitution guidance, and a focused pediatric oncology launch that could expand materially into adolescent, young adult, and adult oncology markets.